Barclays Maintains Overweight on Sotera Health, Raises Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Luke Sergott maintains an Overweight rating on Sotera Health (NASDAQ:SHC) and raises the price target from $14 to $17.
August 06, 2024 | 2:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays analyst Luke Sergott maintains an Overweight rating on Sotera Health and raises the price target from $14 to $17.
The Overweight rating and increased price target from a reputable analyst at Barclays is likely to boost investor confidence in Sotera Health, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100